Treatments

Treatments: It is beyond the scope of BCC’s work to discuss the vast range of breast cancer treatments and interventions. Instead, we highlight key issues in breast cancer treatment as they surface in scientific controversies and public discussions.

See also: Research Briefs


Lymphedema: What Is It? How Can It Be treated?

Nudelman Headshot BWLymphedema is a potential side effect of breast cancer surgery and radiation therapy resulting in the buildup of fluid in the arm. Dr. Judy Nudelman is a Board Certified family medicine physician, a clinical associate professor of family medicine at Brown University, and a certified lymphedema therapist (CLT) who has served on the board of directors of the Lymphology Association of America. She has written textbook chapters and articles on lymphedema and provides education and information to encourage physicians to manage the condition in their patients.

Watch Judy Nudelman’s webinar on lymphedema and how to find a qualified lymphedema therapist »


tamoxifenChemoprevention Is No Magic Bullet

New guidelines for chemoprevention are hailed as “historic” and a “game changer.” Certainly, the promise to reduce the risk of getting breast cancer by 40 to 50 percent sounds great, but if the actual (absolute) numbers are far less impressive – less than 2 percent— and these drugs promote blood clots, cancers, cataracts, and other harms, maybe it’s important to read the fine print and ask some tough questions before getting too excited.

Read More


BrunerPlasticSurgeryCROPRights or Rhetoric? Breast Reconstruction Awareness

Knowing one’s rights as a patient is important. But as breast cancer culture came to focus on the upbeat, life-changing aspects of survivorship, it opened a new consumer market that uses the rhetoric of empowerment and awareness to commercialize almost every aspect of the disease.

Read More


Carcinoma: What’s In A Name?

A working group from the National Cancer Institute suggests eliminating the word “cancer” from some common diagnoses. If patients and physicians are less frightened by the “C” word, they may be less likely to seek treatments that may be unneeded and potentially harmful. The consensus comes after years of considerable discussion in the scientific and medical communities. Read more about the implications of cancer classification and the particular impact on those facing stage zero conditions.

Read More

Related:

Research Brief: Breast Cancer Mortality After a Diagnosis of DCIS by Bonnie Spanier, Breast Cancer Consortium, Oct. 1, 2015.

Should we Rename DCIS? by Jackie Fox, author of From Zero to Mastectomy, Aug. 7, 2013.

What’s In A Name? Cancer – or Indolent Lesions of Epithelial Origin, BCSMCommunity.org, Aug. 5, 2013.


Be Sociable, Share!